Sun Pharma Cancer Drug

• 

  Cancer Drug Prices Slashed Up To 86% In A Year: Regulator

  The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.

• 

  Sun Pharma Launches Cancer Drug In Europe, Shares Gain

  Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe.

• 

  Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug

  Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.

• 

  Sun Pharma Recalls 200 Vials of Cancer Drug: FDA

  The drug being recalled was manufactured by Sun Pharma's unit Caraco Pharmaceutical Laboratories Ltd at its plant in Gujarat, the FDA said in a post on its website.

• Sensex ends 37 points higher amid choppy trade

  The BSE Sensex edged higher in a volatile session on Thursday led by gains in drug maket Sun Pharma, which rose to all-time high on hopes of higher sales of a key cancer drug.

• Sun Pharma rides on cancer drug, hits record high

  Analysts tracking the sector say Sun Pharma already has 50 per cent of the market share in this drug which will get a further boost after this development.

• Sun Pharma gains on US nod for cancer drug

  Shares in Sun Pharmaceutical Industries rose as much as 4.5 percent after the US Food and Drug Administration approved its generic version of ovarian cancer drug Doxil made by Johnson & Johnson in the US market.

• Sun Pharma shares hit; US cancer drug supply contact may end

  Shares in Sun Pharmaceutical Industries fell 1.6 per cent on worries the drug maker will soon see an end to its temporary arrangement to supply a cancer drug in the United States.

• Sun Pharma hit on concerns US cancer drug supply contract may end

  Shares in Sun Pharmaceutical fell 1.6 per cent on worries the drug maker will soon see an end to its temporary arrangement to supply cancer drug Doxil in the United States.

• Sun Pharma shares rise over import of cancer drug Lipodox

  The drug can generate sales of $80-100 million for the company in 4-6 months, which implies potential earnings per share of Rs 3-4 for FY13.

• US court rules against Sun Pharma over cancer drug

  French drugmaker Sanofi today said a US court has ruled in its favour in a patent litigation against Sun Pharmaceuticals over Eloxatin (oxaliplatin), a drug used to treat colon cancer.      The US District Court for the District of New Jersey has ruled against Sun Pharmaceuticals Ltd in favour of Sanofi US, with resp...